Opus Genetics Inc (IRD)

$1.00 0.00 (-0.16%)
Market Cap 31.57M
Revenue (ttm) 19.05M
Net Income (ttm) -9.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -52.44%
Debt to Equity Ratio 0.00
Volume 50,800
Avg Vol 180,726
Day's Range N/A - N/A
Shares Out 31.57M
Stochastic %K 39%
Beta 0.28
Analysts Strong Sell
Price Target $11.00

Latest News on IRD

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Mar 5, 2025, 8:00 AM EST - 3 days ago

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Feb 26, 2025, 8:00 AM EST - 10 days ago

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Feb 18, 2025, 7:30 AM EST - 18 days ago

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

Feb 7, 2025, 9:15 AM EST - 4 weeks ago

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

XBI

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Dec 19, 2024, 8:00 AM EST - 2 months ago

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 12, 2024, 7:59 AM EST - 4 months ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)